Meeting
2023 ASCO Annual Meeting
Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician’s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC).
Authors
Ann Collier
Genentech, Inc., South San Francisco, CA
Ann Collier , Mariana Chavez Mac Gregor , Stephanie Hilz , Aditya Bardia , Joohyuk Sohn , Miguel Martin , Elgene Lim , Jorge Martinalbo , Pablo Diego Pérez-Moreno , Heather M. Moore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT04576455
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1069)
DOI
10.1200/JCO.2023.41.16_suppl.1069
Abstract #
1069
Poster Bd #
290
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2023 ASCO Annual Meeting
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).
First Author: Erica L. Mayer
Poster
2023 ASCO Annual Meeting
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
First Author: Charles Geyer
First Author: Mafalda Oliveira